tradingkey.logo

BUZZ-Kala Bio tumbles after CEO resignation

ReutersFeb 12, 2025 4:55 PM

Shares of drug maker Kala Bio KALA.O fall 34.6% to $7.12, set for record single-day fall

Company says its CEO Mark Iwicki has resigned, and President Todd Bazemore has been appointed as interim CEO

Iwicki has been with KALA for nearly a decade

Iwicki will continue as chair of the board

KALA is set to report mid-stage trial data of its drug, KPI-012, in the second quarter of 2025, for the treatment of persistent corneal epithelial defects, a condition where injuries to the cornea, the clear front part of the eye, don't heal properly

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI